In the last 12 months, insiders at Decoy Therapeutics Inc. ($DCOY) filed 22 transactions with the SEC: 2 open-market purchases totaling $19,741 and 2 sales totaling $17. Net insider sentiment: net buying.
Decoy Therapeutics Inc. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Rosenblum Mark J (Exec VP Finance, CFO) — 4 transactions totaling $16,000
- HANISH ARNOLD C (Director) — 5 transactions totaling $3,758
- McCreedy Bruce J Jr. (Director) — 2 transactions totaling $0
- Arthur David J. (Chief Executive Officer) — 3 transactions totaling $0
- Lieber Jonathan I (Director) — 2 transactions totaling $0
View all SEC Filings for Decoy Therapeutics Inc. (DCOY).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 30, 2025 | HANISH ARNOLD C | Director | S | Common Stock | 12 | $0.64 | 5,000.0000 | 5,862,178 | 0.24% | 0.00% |
| Dec. 30, 2025 | HANISH ARNOLD C | Director | S | Common Stock | 15 | $0.64 | 5,000.0000 | 5,862,178 | 0.30% | 0.00% |
| Nov. 20, 2025 | HANISH ARNOLD C | Director | P | Common Stock | 5000 | $0.75 | 5,027.0000 | 5,862,178 | 9999.99% | 0.09% |
| Nov. 20, 2025 | Rosenblum Mark J | Exec VP Finance, CFO | P | Common Stock | 20000 | $0.80 | 20,177.0000 | 5,862,178 | 9999.99% | 0.34% |
| April 11, 2024 | Arthur David J. | Chief Executive Officer | A | Stock Option (right to buy) | 20500 | $0.00 | 20,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 20, 2024 | Lammers Paul | Director | A | Stock Option (right to buy) | 20500 | $0.00 | 20,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 20, 2024 | Burleson Tess | Director | A | Stock Option (right to buy) | 20500 | $0.00 | 20,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 20, 2024 | HANISH ARNOLD C | Director | A | Stock Option (right to buy) | 20500 | $0.00 | 20,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 20, 2024 | Lieber Jonathan I | Director | A | Stock Option (right to buy) | 20500 | $0.00 | 20,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 20, 2024 | McCreedy Bruce J Jr. | Director | A | Stock Option (right to buy) | 20500 | $0.00 | 20,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 20, 2024 | McVicar William K. | Director | A | Stock Option (right to buy) | 20500 | $0.00 | 20,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 20, 2024 | Rosenblum Mark J | Exec VP Finance, CFO | A | Stock Option (right to buy) | 22500 | $0.00 | 22,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Rosenblum Mark J | Exec VP Finance, CFO | A | Common Stock | 6432 | $0.00 | 21,851.0000 | 0 | 41.71% | 0.00% |
| Feb. 13, 2023 | Arthur David J. | Chief Executive Officer | A | Common Stock | 14300 | $0.00 | 49,135.0000 | 0 | 41.05% | 0.00% |
| Jan. 3, 2023 | HANISH ARNOLD C | Director | A | Common Stock | 1440 | $0.00 | 3,294.0000 | 0 | 77.67% | 0.00% |
| Jan. 3, 2023 | Lammers Paul | Director | A | Common Stock | 1440 | $0.00 | 1,718.0000 | 0 | 517.99% | 0.00% |
| Jan. 3, 2023 | Burleson Tess | Director | A | Common Stock | 1440 | $0.00 | 2,722.0000 | 0 | 112.32% | 0.00% |
| Jan. 3, 2023 | Lieber Jonathan I | Director | A | Common Stock | 1440 | $0.00 | 2,940.0000 | 0 | 96.00% | 0.00% |
| Jan. 3, 2023 | Rosenblum Mark J | Exec VP Finance, CFO | A | Common Stock | 8000 | $0.00 | 15,419.0000 | 0 | 107.83% | 0.00% |
| Jan. 3, 2023 | Arthur David J. | Chief Executive Officer | A | Common Stock | 20000 | $0.00 | 34,835.0000 | 0 | 134.82% | 0.00% |
| Jan. 3, 2023 | McVicar William K. | Director | A | Common Stock | 1440 | $0.00 | 2,850.0000 | 0 | 102.13% | 0.00% |
| Jan. 3, 2023 | McCreedy Bruce J Jr. | Director | A | Common Stock | 1440 | $0.00 | 1,788.0000 | 0 | 413.79% | 0.00% |